Basenese Lou 4

What Happened

• Lou Basenese, a director of ENDRA Life Sciences, was granted 60,324 restricted stock units (RSUs) on January 21, 2026. The transaction is reported as an award/acquisition (code A) at $0.00 per share (total reported value $0).
• These RSUs convert one-for-one into common stock and will vest in full on January 21, 2027 (see footnote F1). This is a compensation award to a director, not an open-market purchase.

Key Details

• Transaction date: 2026-01-21; Form 4 filed: 2026-01-23 (appears timely within the typical two-business-day window).
• Award: 60,324 RSUs; reported price $0.00; reported transaction value $0.
• Vesting: RSUs convert 1-for-1 to common stock and vest in full on 2027-01-21 (F1).
• Holdings note: Filing footnote indicates reported holdings include unvested RSUs (F2). The filing does not list total post-transaction beneficial ownership as a numeric share total.
• Transaction code: A = Award/Grant.

Context

• RSUs are a form of equity compensation that convert to shares upon vesting; recipients typically cannot sell or transfer the underlying shares until they vest and are delivered.
• Grants to directors are common as part of compensation and do not represent an open-market purchase or sale. They should be viewed as compensation, not necessarily a directional signal about insider sentiment.